Navigation Links
New screening approach uncovers potential alternative drug therapies for neuroblastoma
Date:5/23/2013

Nearly two-thirds of patients with high-risk neuroblastoma a common tumor that forms in the nerve cells of childrencannot be cured using tumor-killing cancer drugs. A study published by Cell Press in the May 23 issue of Chemistry & Biology reveals a new genomic approach to screen for compounds that could inhibit tumor growth by causing cancer cells to differentiate, or convert from immature cells to more specialized cell types. Using this screening method, the researchers identified a compound that causes neuroblastoma cells to differentiate, uncovering a promising new treatment strategy for this highly malignant pediatric cancer.

"New treatment approaches are very much needed for children with high-risk childhood cancers; that is, those that are metastatic at diagnosis and likely to recur," says senior study author Kimberly Stegmaier of the Dana-Farber/Children's Hospital Cancer Center and the Broad Institute of the Massachusetts Institute of Technology and Harvard University. "By focusing on an alternative strategy to treating neuroblastoma tumors, we identified a compound class that in early testing in neuroblastoma cells in the laboratory shows promise for treating children with this disease."

Beyond the standard approach of using drugs that kill tumor cells, another promising strategy is to identify compounds that promote differentiation, which causes tumor cells to stop dividing and growing. But the benefits of differentiation therapy had not been fully explored.

To address this need, Stegmaier and her team developed a method to screen small molecules for their ability to trigger differentiation in neuroblastoma cells. First, they treated these cells with drugs known to induce differentiation and looked for accompanying changes in the activity levels of genes. They found that 59 genes showed changes related to differentiation. Using this genetic signature for differentiation, they then screened nearly 2,000 small molecules and identified one compound that strongly promoted differentiation in neuroblastoma cells, especially when combined with a drug already approved to treat this type of cancer.

The newly identified compound works by selectively inhibiting a subset of gene-regulating proteins called histone deacetylases (HDACs). "This work supports the need to develop selective HDAC inhibitors for clinical application and, more broadly, illuminates the power of integrating signature-based screening with new approaches to chemical synthesis to provide novel biological insights into human disease," Stegmaier says.


'/>"/>

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Genetic screening could reveal hidden high risk for coronary heart disease
2. Pulse Oximetry Screening for Newborns a Reality in North Carolina
3. Bay Area Hospital Selects BESLER Consulting’s BVerified (SM)- Screening and Verification Solution
4. Memorial Hospital Wellness Vehicle to Offer Health Screenings at Affordable Assisted Living Community in St. Louis Metro East
5. Water’s Edge Dermatology Offers Complimentary Skin Cancer Screenings in May for Skin Cancer Awareness Month
6. Outsourced Ion Channel Primary Screening Trends & 2015 Forecast in New Market Research Report at ReportsnReports.com
7. PreCheck, Inc. Achieves Background Screening Credentialing Council Accreditation
8. PharmaSmart® and Kinney Drugs Partner up to Unveil Newest Advancement in Pharmacy-Based Biometric Screening and Mobile Interoperability
9. New Guidelines Suggest HIV Screening for All Adults
10. Personalizing prostate cancer screenings
11. Research finds targeted screening for hepatitis C is cost-effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
Breaking Medicine Technology: